AusCann Debut Low-dose Capsules Perfect For Custom Dosing

AusCann announces the successful manufacturing, testing and release of a low-dose presentation of the capsules, at commercial scale.

Medicinal cannabis pharmaceutical company AusCann Group Holdings Limited is pleased to announce that it has completed the manufacturing and testing of its proprietary cannabinoid-based hard-shell capsules in a low-dose presentation.

On 18 December 2019 the Company announced the successful manufacturing, testing and release of a commercial-sized batch of the cannabinoid-based capsules.

The Therapeutic Goods Administration's (TGA) guidance document1 suggests that the general principle for medicinal cannabis dosing should be "start low, go slow.

It is therefore critical to provide doctors and their patients with a controlled-dose formulation in different doses to enable dose titration and personalised treatment

AusCann CEO, Mr Ido Kanyon said that AusCann's ability to customise dosing while ensuring that each capsule is true to label and produced on a commercial scale are factors adding to the competitive advantage of AusCann.

"AusCann has set out to develop cannabinoid-based, controlled-dose capsules patient needs to enable accurate dose titration in a convenient formulation for patients and healthcare professionals. Our ability to customise dosing in an accurate and scalable way will enable doctors to personalise dosing for specific."

Providing true to label customised dosing and enabling customisable treatment of the patient is what differentiates our product in the market." Mr Ido Kanyon, AusCann CEO

"We are providing a medical solution that offers regulated dosages and is in conformance with pharmaceutical quality conformance and regulatory requirements. Our platform is flexible and reliable. We are committed, upon receiving physician and patient feedback from our clinical evaluation, to improving and setting the standard in health outcomes."

"Reliable, stable and standardised medicines are critical in order to generate quality clinical evidence for cannabinoid-based medicines. This evidence is a prerequisite to market expansion and medical acceptance by healthcare professionals.

We remain committed to making our dose-controlled capsules commercially available for prescription to patients in Australia in the first half of 2020 through the TGA special access scheme and authorised prescriber scheme."

To learn more about AusCann visit their Company HQ here

Disclaimer: Past performance is not an indicator of future performance.

Get the Latest Marijuana News &
Content in your Inbox!

All your support helps The Green Fund keep writing content for all you
marijuana enthusiasts and potential pot stock investors

Niki Mohazeb
Niki Mohazeb

Niki is a Sydney based writer, with a passion for promoting the health benefits of medicinal cannabis. Niki also enjoys researching and writing about the future of cannabis along with the many other benefits that the plant provides, such as the diverse utilities of hemp.

Leave a Reply

Your email address will not be published. Required fields are marked *